Illumina, Inc. To Provide Next-Generation Sequencing (NGS) Technologies To Quest Diagnostics Inc.

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced it has entered into a multi-year licensing agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, related to the use of Illumina’s next-generation sequencing technology for clinical laboratory testing.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC